Palynziq is one of BioMarin’s most successfully marketed products. The company added $355 million from the PKU drug’s sales, indicating 17% year-over-year growth, driven by strong commercial ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) just the other day announced that it had achieved positive results from its phase 3 Pegasus trial using its drug Palynziq [pegvaliase] to treat patients ...

BioMarin Pharmaceutical BMRN reported first-quarter 2025 adjusted earnings per share of $1.13, which beat the Zacks Consensus ...

SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its ...

Discover BioMarin's Q1 2025 highlights: 15% revenue growth, VOXZOGO's 40% surge, and innovative R&D initiatives.

BioMarin (BMRN) Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe ...

Palynziq significantly lowered blood Phe levels in adolescents vs. diet alone. BioMarin will submit data for label expansion to health authorities this year. Markets are messy—but the right ...

BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary efficacy endpoint, showcasing a reduction in blood ...

Biomarin Pharmaceutical Inc (BMRN) reports a robust 15% revenue increase and significant profitability expansion, while navigating global market dynamics and strategic investments.

BioMarin BMRN has announced positive results from the phase III PEGASUS study evaluating Palynziq (pegvaliase) in adolescents aged 12-17 years with phenylketonuria (PKU). The study achieved its ...